VytronUS Raises $49M in Series C

What does VytronUS do?

VyTronUS is a private medical device company which is developing novel technologies to treat cardiac arrhythmias. The company is developing next gen integrated imaging and ablation platform for cardiac electrophysilogists. It is using the ultrasound energy capability and is creating a high resolution image of heart’s interior for planning procedures and allowing the physician for simply drawing a desired treatment pattern on the image at the workstation. They offer a winning combo of VT and AF ablation- facile rendering of the 3D left ventricular or atrial anatomy, continous transmural lesions with touching tissue, and mainly the flexibility for the operator defined lesion paths with thickness of tissue info.

How much VytromUS was funded?

The company raised $49M in Series C on July 29, 2016.

Previous funding

$6.6M in Series A on August 20, 2007 from Delphi Ventures and New Enterprise Associates$11M in Series B on June 29, 2009 from Delphi Ventures and New Enterprise Associate

$5.67M on May 16, 2011

$8.7M on February 27, 2012

$2.81M in undisclosed round on March 31, 2013 from New Enterprise Associates

$31.6M in Series B on October 29, 2014 from Apple Tree Partners, Windham Venture Partners and BioStar Ventures

What is next for VytronUS?

The company plans on using the latest funding raised for executing the multi center EU and US clinical validation of their technology. It will alos be used for clinical trisl of its proprietary Low-Intensity Collimated Ultrasound Cardiac Mapping & Ablation system for treating arrhythmia and atrial fibrillation.
More about VytronUS

VytronUS was founded in 2006. It has its headquarters in Sunnyvale, CA. Their systems is designed for enabling physicians in treating complex arrhythmias with unmatched precision, visualization, automation and flexibility.